NDC properties for "0.5 ML Xyosted 150 MG/ML Auto-Injector" (RxCUI 2099697)
About this data
The tables show NDC propoerties for 0.5 ML Xyosted 150 MG/ML Auto-Injector with the RxCUI 2099697
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 0.5 ML Xyosted 150 MG/ML Auto-Injector (RxCUI 2099697)
| MMSL_CODE | BD33832 |
|---|---|
| NDA | NDA209863 |
| RxCUI | 2099697 |
| SPL_SET_ID | 8a3d204c-be26-49e0-8599-0ac12a272e81 |
| Prescribable Synonym | XYOSTED 75 MG in 0.5 ML Auto-Injector |
| RXNAV_STR | 0.5 ML Xyosted 150 MG/ML Auto-Injector |
| RxNorm Name | 0.5 ML testosterone enanthate 150 MG/ML Auto-Injector [Xyosted] |
| RxNorm Synonym | 0.5 ML Xyosted 150 MG/ML Auto-Injector |
| RxNorm Synonym | XYOSTED 75 MG per 0.5 ML Auto-Injector |
| Related queries | Interactions (for RxCUI 2099697) |
NDC Properties
NDC Item 54436027501
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-01 |
| NDC Item | 54436027501 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027502
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-02 |
| NDC Item | 54436027502 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027503
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-03 |
| NDC Item | 54436027503 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027504
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-04 |
| NDC Item | 54436027504 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027505
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-05 |
| NDC Item | 54436027505 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027501
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-01 |
| NDC Item | 54436027501 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027502
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-02 |
| NDC Item | 54436027502 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027503
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-03 |
| NDC Item | 54436027503 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027504
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-04 |
| NDC Item | 54436027504 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027505
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-05 |
| NDC Item | 54436027505 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027501
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-01 |
| NDC Item | 54436027501 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027502
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-02 |
| NDC Item | 54436027502 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027503
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-03 |
| NDC Item | 54436027503 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027504
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-04 |
| NDC Item | 54436027504 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027505
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-05 |
| NDC Item | 54436027505 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027501
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-01 |
| NDC Item | 54436027501 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027502
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-02 |
| NDC Item | 54436027502 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027503
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-03 |
| NDC Item | 54436027503 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027504
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-04 |
| NDC Item | 54436027504 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027505
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-05 |
| NDC Item | 54436027505 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027501
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-01 |
| NDC Item | 54436027501 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-01) / .5 mL in 1 SYRINGE (54436-275-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027502
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-02 |
| NDC Item | 54436027502 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027503
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-03 |
| NDC Item | 54436027503 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027504
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-04 |
| NDC Item | 54436027504 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-275-04) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |
NDC Item 54436027505
| NDC 9 | 54436-275 |
|---|---|
| NDC 10 | 54436-275-05 |
| NDC Item | 54436027505 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-275-05) / .5 mL in 1 SYRINGE (54436-275-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-275 |